158 related articles for article (PubMed ID: 10037459)
1. Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.
Cooper AJ; Sheu KF; Burke JR; Strittmatter WJ; Gentile V; Peluso G; Blass JP
J Neurochem; 1999 Mar; 72(3):889-99. PubMed ID: 10037459
[TBL] [Abstract][Full Text] [Related]
2. Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases.
Cooper AJ; Wang J; Pasternack R; Fuchsbauer HL; Sheu RK; Blass JP
Dev Neurosci; 2000; 22(5-6):404-17. PubMed ID: 11111157
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length.
Cooper AJ; Sheu KR; Burke JR; Onodera O; Strittmatter WJ; Roses AD; Blass JP
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12604-9. PubMed ID: 9356496
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
De Vivo G; Gentile V
CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):370-5. PubMed ID: 18991665
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats.
Ruoppolo M; Orrù S; Francese S; Caputo I; Esposito C
Protein Sci; 2003 Jan; 12(1):170-9. PubMed ID: 12493840
[TBL] [Abstract][Full Text] [Related]
6. Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases.
Gentile V; Sepe C; Calvani M; Melone MA; Cotrufo R; Cooper AJ; Blass JP; Peluso G
Arch Biochem Biophys; 1998 Apr; 352(2):314-21. PubMed ID: 9587422
[TBL] [Abstract][Full Text] [Related]
7. Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases?
Cooper AJ; Jeitner TM; Gentile V; Blass JP
Neurochem Int; 2002 Jan; 40(1):53-67. PubMed ID: 11738472
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.
Hoffner G; André W; Vanhoutteghem A; Souès S; Djian P
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):217-31. PubMed ID: 19811443
[TBL] [Abstract][Full Text] [Related]
9. Polyglutamine domains are substrates of tissue transglutaminase: does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?
Cooper AJ; Sheu KF; Burke JR; Onodera O; Strittmatter WJ; Roses AD; Blass JP
J Neurochem; 1997 Jul; 69(1):431-4. PubMed ID: 9202340
[TBL] [Abstract][Full Text] [Related]
10. The multifaceted role of transglutaminase in neurodegeneration: review article.
Karpuj M; Steinman L
Amino Acids; 2004 Jul; 26(4):373-9. PubMed ID: 15290343
[TBL] [Abstract][Full Text] [Related]
11. Glial and neuronal expression of polyglutamine proteins induce behavioral changes and aggregate formation in Drosophila.
Kretzschmar D; Tschäpe J; Bettencourt Da Cruz A; Asan E; Poeck B; Strauss R; Pflugfelder GO
Glia; 2005 Jan; 49(1):59-72. PubMed ID: 15390099
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Iannaccone M; Serretiello E; De Vivo G; Martin A; Stefanile A; Titta F; Gentile V
Recent Pat CNS Drug Discov; 2013 Aug; 8(2):161-8. PubMed ID: 23688272
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase and diseases of the central nervous system.
Hoffner G; Djian P
Front Biosci; 2005 Sep; 10():3078-92. PubMed ID: 15970562
[TBL] [Abstract][Full Text] [Related]
14. Transglutaminase cross-links in intranuclear inclusions in Huntington disease.
Zainelli GM; Ross CA; Troncoso JC; Muma NA
J Neuropathol Exp Neurol; 2003 Jan; 62(1):14-24. PubMed ID: 12528814
[TBL] [Abstract][Full Text] [Related]
15. Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Martin A; De Vivo G; Ricotta M; Iannuzzi M; Gentile V
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):195-202. PubMed ID: 20636272
[TBL] [Abstract][Full Text] [Related]
16. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch.
Igarashi S; Koide R; Shimohata T; Yamada M; Hayashi Y; Takano H; Date H; Oyake M; Sato T; Sato A; Egawa S; Ikeuchi T; Tanaka H; Nakano R; Tanaka K; Hozumi I; Inuzuka T; Takahashi H; Tsuji S
Nat Genet; 1998 Feb; 18(2):111-7. PubMed ID: 9462738
[TBL] [Abstract][Full Text] [Related]
17. Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Iannaccone M; Titta F; Serretiello E; Monfregola M; Gentile V
Recent Pat CNS Drug Discov; 2014; 9(2):76-84. PubMed ID: 25386917
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
Iannaccone M; Titta F; Serretiello E; De Vivo G; Martin A; Gentile V
Recent Pat CNS Drug Discov; 2013 Dec; 8(3):235-42. PubMed ID: 24286449
[TBL] [Abstract][Full Text] [Related]
19. Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease.
Mackenzie IR; Butland SL; Devon RS; Dwosh E; Feldman H; Lindholm C; Neal SJ; Ouellette BF; Leavitt BR
BMC Neurol; 2006 Aug; 6():32. PubMed ID: 16945149
[TBL] [Abstract][Full Text] [Related]
20. [Polyglutamine diseases: a pathologic view].
Yamada M
Rinsho Shinkeigaku; 2003 Nov; 43(11):903-5. PubMed ID: 15152499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
